Literature DB >> 17431552

[Infection control measures and surveillance of patients with ventricular assist devices].

F Mattner1, I F Chaberny, L Mattner, P Gastmeier, R Tessmann, M Strüber.   

Abstract

Ventricular assist devices (VAD) are a new routine therapy option for end-stage heart failure. However, the incidence of VAD-related infections varies between 20 and 188% and makes a major contribution to VAD-related morbidity. Therefore, optimised infection control policies should be applied to prevent VAD-related infections. As to date only a few studies exist investigating particular prevention measures for VAD recipients, we have tried to adapt evidence-based guidelines. In detail the following preventive measures are discussed: antibiotic prophylaxis, endocarditis prophylaxis, dressing technique for the driveline-exit site and education of patients and medical staff. A new patient-based surveillance system is proposed which reflects the different times since implantation of VADs and therefore allows a fair method for interhospital comparison.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17431552     DOI: 10.1007/s00101-007-1155-3

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  45 in total

1.  Development of an infection-resistant LVAD driveline: a novel approach to the prevention of device-related infections.

Authors:  L Choi; A F Choudhri; V G Pillarisetty; L A Sampath; L Caraos; S R Brunnert; M C Oz; S M Modak
Journal:  J Heart Lung Transplant       Date:  1999-11       Impact factor: 10.247

2.  Infection: an Achilles heel of destination left ventricular assist device therapy.

Authors:  Julie A Shinn
Journal:  Prog Cardiovasc Nurs       Date:  2005

3.  Comparison of Novacor and HeartMate vented electric left ventricular assist devices in a single institution.

Authors:  Anantharam V Kalya; Alfred J Tector; John D Crouch; Francis X Downey; Monica L McDonald; Alfred J Anderson; Carla J Bartoszewski; Jeffery D Hosenpud
Journal:  J Heart Lung Transplant       Date:  2005-11       Impact factor: 10.247

4.  Nursing care of the ambulatory patient with a mechanical assist device.

Authors:  J E Reedy; S A Ruzevich; N R Noedel; L J Vitale; E J Merkle
Journal:  J Heart Transplant       Date:  1990 Mar-Apr

5.  Midterm follow-up of patients discharged from hospital under left ventricular assistance.

Authors:  A El-Banayosy; O Fey; P Sarnowski; L Arusoglu; D Boethig; H Milting; M Morshuis; R Körfer
Journal:  J Heart Lung Transplant       Date:  2001-01       Impact factor: 10.247

6.  Multicenter clinical evaluation of the HeartMate vented electric left ventricular assist system in patients awaiting heart transplantation.

Authors:  O H Frazier; E A Rose; M C Oz; W Dembitsky; P McCarthy; B Radovancevic; V L Poirier; K A Dasse
Journal:  J Thorac Cardiovasc Surg       Date:  2001-12       Impact factor: 5.209

7.  Morbidity and outcome after mechanical ventricular support using Thoratec, Novacor, and HeartMate for bridging to heart transplantation.

Authors:  K Minami; A El-Banayosy; A Sezai; L Arusoglu; P Sarnowsky; O Fey; R Koerfer
Journal:  Artif Organs       Date:  2000-06       Impact factor: 3.094

Review 8.  Managing the post-left ventricular assist device patient.

Authors:  Charles T Klodell; Edward D Staples; Juan M Aranda; Richard S Schofield; James A Hill; Daniel F Pauly; Thomas M Beaver
Journal:  Congest Heart Fail       Date:  2006 Jan-Feb

9.  Oral surgical management of patients with mechanical circulatory support.

Authors:  J P Lund; T Drews; R Hetzer; P A Reichart
Journal:  Int J Oral Maxillofac Surg       Date:  2002-12       Impact factor: 2.789

10.  LVAD bloodstream infections: therapeutic rationale for transplantation after LVAD infection.

Authors:  Robert S Poston; Shahid Husain; Damian Sorce; Ellieen Stanford; Shimon Kusne; Margaret Wagener; Bartley P Griffith; Robert L Kormos
Journal:  J Heart Lung Transplant       Date:  2003-08       Impact factor: 10.247

View more
  1 in total

Review 1.  Ventricular Assist Device-Specific Infections.

Authors:  Yue Qu; Anton Y Peleg; David McGiffin
Journal:  J Clin Med       Date:  2021-01-25       Impact factor: 4.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.